AnTolRx Secures $4,000,000 Series A Funding Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    Building 1400 West Cambridge, MA 02139 USA
  • Company Description
    At AnTolRx we are approaching the treatment of autoimmune diseases differently–through the development of novel nanoparticle-based therapies to promote antigen-specific immune tolerance. Standard therapies broadly suppress the immune system, inducing side effects that may include life threatening infections and tumors.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    We are grateful for the funding and support we have received from Pfizer, JDRF and Orion, as we continue to focus on developing disease-modifying therapies for patients with immune disorders, including type 1 diabetes, multiple sclerosis and inflammatory bowel disease.
  • M&A Terms
  • Venture Investor
    Pfizer Venture Investments
  • Venture Investor
    Orion Equity Partners
  • Venture Investor

Trending on Xconomy